Impact of Oral DFD-29, a Low-Dose Formulation of Minocycline, on Quality of Life in Patients with Rosacea: Results of Two Phase 3 Randomized Controlled Trials.
These data suggest that DFD-29 may be useful in improving QoL in patients with moderate-to-severe rosacea.
Authors
- Thomas Dirschka (ORCID: https://orcid.org/0000-0001-7804-5311)
- Linda Stein Gold (ORCID: https://orcid.org/0000-0002-2758-1605)
- Paul S. Yamauchi
- Srinivas Sidgiddi
- Sunil Dhawan
- Athanasios Tsianakas (ORCID: https://orcid.org/0000-0002-3430-4251)
Institutions
- Henry Ford Health System (US)
- Witten/Herdecke University (DE)
- Christoffel Blinden Mission (DE)
- Electronics for Imaging (United States) (US)
- First Candle (US)
- Skin Health Institute (AU)
Publication Details
- Journal
- PubMed
- Published
- 2025-10-01
- Primary Topic
- Acne and Rosacea Treatments and Effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00